RecruitingPhase 1ACTRN12606000238572

ERYTHROPOIETIN STUDY

Feasibility and safety of erythropoietin (EPO) administration in patients with acute myocardial infarction (AMI) to improve cardiac function and remodelling.

Sponsor

Eastern Heart Clinic

Enrollment

20 participants

Start Date

Jun 7, 2006

Study Type

Interventional

Conditions

Acute Myocardial Infarction (AMI)

Summary

The purpose of this study is to test the feasibility and safety of intravenous erythropoietin (EPO) injections in patients with recent acute myocardial infarction to improve cardiac remodelling and cardiac function

Eligibility

Sex: Both males and femalesMin Age: 18 Yearss

Plain Language Summary

Simplified for easier understanding

This study is testing whether a hormone called erythropoietin (EPO), given intravenously after a heart attack, can help the heart recover and work better. EPO is already used to treat anaemia, but researchers think it may also protect and help repair heart muscle after a heart attack. This early phase study is primarily checking whether the treatment is safe and practical. You may be eligible if: - You are 18 years or older - You have had an acute ST elevation heart attack (a type of serious heart attack) - You were treated with angioplasty and stenting as emergency treatment - Your heart muscle function is significantly reduced following the heart attack You may NOT be eligible if: - You have multiple or major other serious health conditions Talk to your doctor about whether this trial might be right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

Erythropoietin administration (10000units given as a one-off [single dose] intravenous bolus dose) within 24 hours of primary percutaneous intervention to treat patients with AMI. As this is a phase I safety study all subjects will receive open-label erythropoietin and there will be no control group or comparitor.